NEW YORK, March 5, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed
Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array
BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive
these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
Pfizer Inc. Analyst Notes
On March 3, 2014, Pfizer Inc.'s
(Pfizer) stock decreased 0.40% to end the day at $31.98, compared to the previous day's closing
price at $32.11. Pfizer's stock
decreased 0.03% over the past three trading days, compared to the
Dow Jones Industrial Average which went down 0.19% during the same
trading period. The full analyst notes on Pfizer Inc. are available
to download free of charge at:
http://www.AnalystsReview.com/03052014/PFE/report.pdf
--
Dendreon Corp. Analyst Notes
On March 3, 2014, Dendreon Corp.
(Dendreon) reported its Q4 2013 and full-year 2013 financial
results. For Q4 2013, net product revenues totaled $74.8 million compared to $85.5 million in Q4 2012. For full year 2013, net
product revenue totaled $283.7
million, down 12.8% YoY. Full-year net loss was $296.8 million or $1.95 per diluted share, compared to $393.6 million or $2.65 per share in full year 2012. "During the
fourth quarter, our results were driven by strong growth in our
oncology accounts as well as improvements in urology and academic
accounts," said John H. Johnson,
Chairman, President and CEO of Dendreon. "We expect our first
quarter 2014 revenues to be consistent with our first quarter 2013
results. We continue to be on track on our restructuring and cost
reduction plan to accelerate the path to profitability. We are
focused on becoming cash flow breakeven as soon as possible." The
full analyst notes on Dendreon Corp. are available to download free
of charge at:
http://www.AnalystsReview.com/03052014/DNDN/report.pdf
--
DepoMed Inc. Analyst Notes
On February 25, 2014, DepoMed Inc.
(Depomed) reported its preliminary, unaudited Q4 2013 financial
results. The Company's preliminary information suggested that
product sales are expected to be c. $18.8
million for Q4 2013 compared to $12.5
million in Q4 2012, and $58.3
million for full year 2013 compared to $27.5 million in 2012. According to the Company,
for Q4 2013, license and other revenue is expected to be c.
$3.3 million while royalty revenue is
expected to be $0.4 million. Depomed
anticipates Q4 2013 total operating expenses to be $31 million. "2013 was a transformational year
for Depomed," noted Jim Schoeneck,
President and CEO of Depomed. "We executed a series of transactions
that cement our position as a leading specialty pharmaceutical
company in pain and neurology. With $276
million in purchasing power pending final determination of
our 2013 income taxes, we have the financial resources to continue
to build our portfolio of high growth products in pain, neurology
and adjacent areas." The full analyst notes on DepoMed Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03052014/DEPO/report.pdf
--
Globus Medical, Inc. Analyst Notes
On February 26, 2014, Globus
Medical, Inc. (Globus) reported its Q4 2013 financial results. For
the quarter, the Company registered worldwide sales of $115.2 million, up 14.6% YoY. Q4 2013 net income
totaled $21.0 million or $0.22 per diluted share, compared to $20.8 million or $0.22 per diluted share in Q4 2012. For full year
2013, worldwide sales totaled $434.5
million, up 12.6% YoY. Full-year 2013 net income was
$68.6 million or $0.73 per diluted share, compared to $73.8 million or $0.80 per diluted share in 2012. "2013 was an
outstanding year for Globus Medical. Sales grew by 12.6%, reaching
$434.5 million; our full year
Adjusted EBITDA was 34.7% of sales; we launched 16 new products;
and we completed the acquisition of Excelsius Surgical," commented
David Paul, Chairman and CEO. "This
performance was the result of consistent, sustained execution of
our strategy of combining robust product innovation and continued
sales force expansion with disciplined expense control. I am very
proud of the performance of our team in 2013 and continue to be
confident in our ability to produce industry leading growth and
outstanding profitability." The full analyst notes on Globus
Medical, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/GMED/report.pdf
--
Array BioPharma, Inc. Analyst
Notes
On March 3, 2014, Array BioPharma
Inc. (Array) reported full results from a randomized Phase 2 trial
of ARRY 502 in patients with mild to moderate Th2-Driven Asthma.
The results presented at the 2014 American Academy Of Allergy,
Asthma & Immunology (AAAAI) Annual Meeting suggested that
ARRY-502 met the primary endpoint in the trial, showing improved
pre-bronchodilator Forced Expiratory Volume in one second (FEV1), a
measure of lung function, by 3.9% versus placebo, achieving
statistical significance. According to the release, ARRY-502 was
well tolerated, with fewer adverse events in the ARRY-502 group as
compared to the placebo group, including fewer asthma
exacerbations. Ron Squarer, CEO of Array, noted, "With many asthma
patients poorly controlled on currently available therapies,
especially among severe asthmatics, an oral drug targeting a novel
anti-inflammatory mechanism may present an important new option for
millions of patients. We are seeking an appropriate partner to
develop ARRY-502 to its full potential." The full analyst notes on
Array BioPharma, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03052014/ARRY/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review